Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 2
2010 2
2011 4
2012 7
2013 2
2014 3
2015 3
2016 7
2017 7
2018 9
2019 10
2020 15
2021 23
2022 30
2023 18
2024 22
2025 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Results by year

Filters applied: . Clear all
Page 1
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, Jackson DJ, Roufosse F, Börjesson Sjö L, Fan Y, Jison M, McCrae C, Necander S, Shavit A, Walton C, Merkel PA; MANDARA Study Group. Wechsler ME, et al. N Engl J Med. 2024 Mar 7;390(10):911-921. doi: 10.1056/NEJMoa2311155. Epub 2024 Feb 23. N Engl J Med. 2024. PMID: 38393328 Clinical Trial.
Mepolizumab treatment in patients with severe eosinophilic asthma.
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators. Ortega HG, et al. N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. N Engl J Med. 2014. PMID: 25199059 Free article. Clinical Trial.
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, Harris SS, Mayer B, Rubin DB, Yancey SW, Sciurba FC. Pavord ID, et al. Among authors: lugogo n. N Engl J Med. 2017 Oct 26;377(17):1613-1629. doi: 10.1056/NEJMoa1708208. Epub 2017 Sep 11. N Engl J Med. 2017. PMID: 28893134 Free article. Clinical Trial.
Reply.
Cardet JC, Jiang X, Lu Q, Gerard N, McIntire K, Boushey HA, Castro M, Chinchilli VM, Codispoti CD, Dyer AM, Holguin F, Kraft M, Lazarus S, Lemanske RF, Lugogo N, Mauger D, Moore WC, Moy J, Ortega VE, Peters SP, Smith LJ, Solway J, Sorkness CA, Sumino K, Wechsler ME, Wenzel S, Israel E; AsthmaNet Investigators. Cardet JC, et al. Among authors: lugogo n. J Allergy Clin Immunol. 2019 Sep;144(3):873-874. doi: 10.1016/j.jaci.2019.05.029. Epub 2019 Jul 9. J Allergy Clin Immunol. 2019. PMID: 31300279 No abstract available.
Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Criner GJ, et al. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112385 Clinical Trial.
Asthma [Internet].
Smith JD, Arteta M, Baptist AP, Van Harrison R, Kelley SA, Lindell VA, Lugogo NL, Noble JA, Rew KT, Van Harrison R, Proudlock AL. Smith JD, et al. Among authors: lugogo nl. Ann Arbor (MI): Michigan Medicine University of Michigan; 2021 Jul. Ann Arbor (MI): Michigan Medicine University of Michigan; 2021 Jul. PMID: 35412724 Free Books & Documents. Review.
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators. Nair P, et al. Among authors: lugogo nl. N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22. N Engl J Med. 2017. PMID: 28530840 Free article. Clinical Trial.
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, Griffiths JM, Sałapa K, Hellqvist Å, Almqvist G, Lal H, Kaur P, Skärby T, Colice G; SOURCE study group. Wechsler ME, et al. Lancet Respir Med. 2022 Jul;10(7):650-660. doi: 10.1016/S2213-2600(21)00537-3. Epub 2022 Mar 29. Lancet Respir Med. 2022. PMID: 35364018 Clinical Trial.
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, Roseti SL, Ambrose CS, Hunter G, Jackson DJ, Castro M, Lugogo N, Pavord ID, Martin N, Brightling CE. Wechsler ME, et al. Among authors: lugogo n. Eur Respir J. 2024 Dec 5;64(6):2400316. doi: 10.1183/13993003.00316-2024. Print 2024 Dec. Eur Respir J. 2024. PMID: 39326921 Free PMC article. Clinical Trial.
161 results